As of Thursday close, Chinook Therapeutics Inc.’s (NASDAQ:KDNY) stock was up $0.1, moving up 0.25 percent to $40.29. The average number of shares traded per day over the past five days has been 4,777,180 shares. 3 times new highs have been achieved over the past 5 days, with a $1.36 gain in that time frame. In the last twenty days, the average volume was 1,745,830, while in the previous 50 days, it was 1,957,494.
Since last month, KDNY stock rose 4.11%. Shares of the company fell to $38.53 on 07/05/23, the lowest level in the past month. A 52-week high of $40.47 was reached on 08/01/23 after having rallying from a 52-week low of $18.34. Since the beginning of this year, KDNY’s stock price has risen by 53.78% or $14.09, and marked a new high 13 times. However, the stock has declined by -0.44% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
KDNY stock investors should be aware that Chinook Therapeutics Inc. (KDNY) stock had its last reported insider trading activity 3 days ago on Aug 01. King Andrew James, the Chief Scientific Officer of the company, disposed of 1,168 shares for $39.03 on Aug 01. It resulted in a $45,586 divestment by the insider. Greenman William Mariner sold 1,155 shares at an average price of $23.30 on May 30. The insider now owns 23,643 shares following the transaction. On Apr 24, President, CEO DOBMEIER ERIC sold 23,800 shares at $21.58 apiece. The transaction was valued at $513,528.
Valuation Metrics
The stock’s beta is 0.31. Besides these, the trailing price-to-sales (P/S) ratio of 507.73, the price-to-book (PB) ratio of 6.91.
Financial Health
In the three months ended March 30, Chinook Therapeutics Inc.’s quick ratio stood at 7.00, while its current ratio was 7.00, showing that the company is able to pay off its debt. Based on annual data, KDNY earned $191.21 million in gross profit and brought in $6.13 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -42.90%. Return on equity (ROE) for the past 12 months was -47.10%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. KDNY’s revenue fell -47.54% to $0.51 million during the quarter, while net income inched up to $1.83 million. While analysts expected Chinook Therapeutics Inc. to report -$0.79 quarterly earnings, the actual figure was -$0.85 per share, beating the consensus estimate by -7.60%. During the quarter, the company generated -$61.5 million in EBITDA. The liabilities of Chinook Therapeutics Inc. were 131.48 million at the end of its most recent quarter ended March 30, and its total debt was $38.26 million. The value of shareholders’ equity is $66.89 million.
Technical Picture
This quick technical analysis looks at Chinook Therapeutics Inc.’s (KDNY) price momentum. With a historical volatility rate of 14.56%, the RSI 9-day stood at 78.51% on 03 August.
With respect to its five-day moving average, the current Chinook Therapeutics Inc. price is up by +3.49% percent or $1.36. At present, KDNY shares trade +2.73% above its 20-day simple moving average and +83.47% percent above its 100-day simple moving average. However, the stock is currently trading approximately +82.14% above its SMA50 and +110.17% above its SMA200.
Stochastic coefficient K was 86.75% and Stochastic coefficient D was 71.89%, while ATR was 0.39. Given the Stochastic reading of 88.82% for the 14-day period, the RSI (14) reading has been calculated as 78.84%. As of today, the MACD Oscillator reading stands at 0.77, while the 14-day reading stands at 0.88.
Analyst Ratings
Piper Sandler launched its rating on Chinook Therapeutics Inc. (NASDAQ: KDNY) to an Overweight in a note to investors on March 06, 2023. Chinook Therapeutics Inc. (KDNY) has been rated Hold by analysts. According to 0 brokerage firms, KDNY is a sell, and 9 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Chinook Therapeutics Inc. stock as buy, with 2 recommending it as overweight.
With a median target price of $40.00, the current consensus forecast for the stock is $40.00 – $47.00. Based on these forecasts, analysts predict Chinook Therapeutics Inc. (KDNY) will achieve an average price target of $41.10.
